Paragon Care Limited (ASX:PGC)
Australia · Delayed Price · Currency is AUD | Market Cap | 231.74M -65.0% |
| Revenue (ttm) | 3.68B +1.8% |
| Net Income | -16.03M |
| EPS | -0.01 |
| Shares Out | 1.66B |
| PE Ratio | n/a |
| Forward PE | 8.57 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 899,463 |
| Open | 0.1400 |
| Previous Close | 0.1400 |
| Day's Range | 0.1350 - 0.1450 |
| 52-Week Range | 0.1250 - 0.4000 |
| Beta | -0.30 |
| Analysts | Buy |
| Price Target | 0.24 (+77.78%) |
| Earnings Date | Aug 26, 2026 |
About Paragon Care
Paragon Care Limited distributes medical equipment, devices, and consumable products in Australia, New Zealand, and Asia. The company designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohematology laboratories; offers ophthalmology and optometry, neonatal vision screening solutions, and procedural kits. It also provides neonatal and paediatric assessment, including newborn hearing and vision screening, jaundice management, NICU video monitoring, brain monitoring, b... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for PGC stock is "Buy." The 12-month stock price target is $0.24, which is an increase of 77.78% from the latest price.
News
Paragon Care Earnings Call Transcript: H2 2026
Underlying revenue was AUD 3.7 billion with normalized EBITDA growth of 7.4% and strong organic growth after adjusting for major one-offs. Six acquisitions expanded the business across APAC, while a share buyback is planned for FY 2027. Focus shifts to organic growth and operational efficiency.
Paragon Care Annual report: H2 2026
Paragon Care has published its H2 2026 annual report on August 25, 2026.
Paragon Care Earnings release: H2 2026
Paragon Care released its H2 2026 earnings on August 25, 2026, summarizing the period's financial results.
Paragon Care Slides: H2 2026
Paragon Care has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 25, 2026.
Paragon Care Earnings Call Transcript: H1 2026
Underlying revenue reached AUD 1.9 billion with EBITDA of AUD 49 million, while statutory results were impacted by a full provision for Infinity Group debt. Strong organic and segment growth, major contract wins, and ongoing integration support positive guidance, with net debt targeted at 2x EBITDA by June.
Paragon Care Quarterly report: H1 2026
Paragon Care has published its H1 2026 quarterly earnings report on February 24, 2026.
Paragon Care Slides: H1 2026
Paragon Care has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 24, 2026.
Paragon Care Earnings release: H1 2026
Paragon Care released its H1 2026 earnings on February 24, 2026, summarizing the period's financial results.
Paragon Care Earnings Call Transcript: H2 2025
Revenue grew 8.3% to $3.6 billion and underlying EBITDA rose 3% to $95.2 million, driven by strong Asia-Pacific and pharmacy performance. Integration synergies of $5 million were achieved, with $12 million targeted for FY 2026, and a $400 million refinancing improved capital flexibility.
Paragon Care Annual report: H2 2025
Paragon Care has published its H2 2025 annual report on August 26, 2025.
Paragon Care Slides: H2 2025
Paragon Care has posted slides in relation to its H2 2025 quarterly earnings report, which was published on August 26, 2025.
Paragon Care Earnings release: H2 2025
Paragon Care released its H2 2025 earnings on August 26, 2025, summarizing the period's financial results.